Glioblastoma is a devastating disease for both patients and caregivers due to the high rate of recurrence, limited treatment options and aggressive nature of the disease.i, ii , According to the World Health Organization (WHO), globally, the estimated incidence of brain and nervous systems cancers is approximately 250,000.iii Learn more about this type of biologically aggressive brain tumor.
AbbVie’s researchers are tackling some of the most difficult to treat cancers. Learn about how AbbVie’s Kyle Holen brought his passion to help people living with glioblastoma from clinical practice to the research lab.
References:
i Weller M, Cloughsey T et al. Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro Oncol (2013) 15 (1): 4-27.
ii National Brain Tumor Society. (2016) TUMOR TYPES: UNDERSTANDING BRAIN TUMORS. [ONLINE] Accessed October 2016.
iii WHO, IARC, Globocan Cancer Incidence and Mortality Worldwide in 2012. Last accessed March 2017 at http:// globocan.iarc.fr/
Media inquiries:
Kelli Teno
Email: kelli.teno@abbvie.com
Call: +1 847-935-9593
